All In Biotech

Drug Trial Radar · NCT06130553

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced/Metastatic Solid Tumors That Are MTAP Deficient

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

334

Planned (sponsor's estimate)

Start

Jan 18, 2024

Primary completion

Dec 4, 2028

Study completion Dec 4, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several study modules, evaluating the safety, tolerability, pharmacokinetic (PK), pharmacodynamics, and preliminary efficacy of AZD3470 as monotherapy or in combination with other anti-cancer agents.

Conditions

  • Advanced Solid Tumors That Are MTAP Deficient

Interventions

  • AZD3470Drug

    AZD3470 is a novel, potent and selective, second-generation, MTAP-selective, inhibitor of PRMT5.

  • Datopotamab deruxtecanDrug

    AZD3470 in combination with Dato-DXd + Dato-Dxd monotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All Modules: Incidence of adverse events (AEs) and serious adverse events (SAEs). To determine the RP2D of AZD3470 as monotherapy and in combination with anticancer agentsTime frame: From time of informed consent to 28 days post last dose of study treatment
  2. Module 1: Incidence of dose-limiting toxicities (DLT)Time frame: From first dose of study treatment until the end of Cycle 1 (each cycle is 21 days)
  3. Module 2: Progression Free Survival assessed by the Investigator according to RECIST v1.1Time frame: From date of randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years).

Locations

21 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    San Francisco, California · Recruiting

  • Research Site

    West Hollywood, California · Withdrawn

  • Research Site

    New Haven, Connecticut · Recruiting

  • Research Site

    Baltimore, Maryland · Recruiting

  • Research Site

    Portland, Oregon · Recruiting

  • Research Site

    Pittsburgh, Pennsylvania · Recruiting

  • Research Site

    Providence, Rhode Island · Recruiting

  • Research Site

    Fairfax, Virginia · Recruiting

  • Research Site

    Melbourne, Australia · Recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Wuhan, China · Not yet recruiting

  • Research Site

    Villejuif, France · Not yet recruiting

  • Research Site

    Chūōku, Japan · Recruiting

  • Research Site

    Kashiwa, Japan · Recruiting

  • Research Site

    Amsterdam, Netherlands · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Barcelona, Spain · Recruiting

  • Research Site

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.